Avinash Desai, MD
Actinium Pharmaceuticals, Inc. · Actinium Pharmaceuticals · Actinium Pharmaceuticals Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Avinash Desai, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:42 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03932318 · Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML PatientsActinium Pharmaceuticals · withdrawn · Acute Myeloid Leukemia, Relapsed Adult AML · study chair
- Ph1/Ph2NCT03867682 · Venetoclax and Lintuzumab-Ac225 in AML PatientsActinium Pharmaceuticals · unknown · Acute Myeloid Leukemia, Relapsed Adult AML · study chair
- Ph1NCT02998047 · A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple MyelomaActinium Pharmaceuticals · terminated · Refractory Multiple Myeloma · study director
- Ph3NCT02665065 · Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid LeukemiaActinium Pharmaceuticals · active not recruiting · Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute · study chair
- Ph1/Ph2NCT02575963 · Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) PatientsActinium Pharmaceuticals · completed · AML · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in acute myeloid leukemia.